-
Sage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing
Tuesday, September 12, 2017 - 11:29am | 321Shares of SAGE Therapeutics Inc (NASDAQ: SAGE) plunged Tuesday after the biopharma company announced its treatment for super-refractory status epilepticus failed its phase III trial. Chardan analyst Gbola Amusa rated the stock a Hold and said a price target was under review. Shares Fall Off A Cliff...